Hotcakes: Low LDL, New Pain Meds, SGLT2i & PAD, and Transfusion Strategies

Cognitive Safety of Very Low LDL

• 💡 The Ebbinghaus-Olay study investigated the long-term cognitive safety of achieving very low LDL cholesterol with evolocumab.
• ⚠️ While some express concerns about very low LDL levels (20-50 mg/dL), this study found no cognitive decline over 5 years in patients taking PCSK9 inhibitors.
• 🧠 The study had limitations, including being an open-label extension with a potentially highly selected patient population and a relatively young average age.
• 📈 Further long-term follow-up and new study methods are needed to definitively assess cognitive effects in older or longer-term treated populations.

Suzetrigine for Acute Pain

• 🚀 Suzetrigine is a novel non-opioid oral pain medication, the first in a new class approved for acute pain.
• 🎯 The phase 2 trial showed suzetrigine provided better pain relief for postoperative soft tissue and bony pain compared to placebo and hydrocodone-acetaminophen.
• ⚠️ Key limitations included a vague exclusion criteria, lack of a consort diagram, and a small dose of hydrocodone used as a comparator.
• 🩺 While promising as a non-addictive alternative, more data from larger trials (Navigate 1 & 2) is needed to fully understand its efficacy and role in multimodal pain management.

SGLT2 Inhibitors and Peripheral Artery Disease

• ⚠️ A retrospective study on US veterans examined the risk of Peripheral Artery Disease (PAD) events, including amputations, with SGLT2 inhibitors versus DPP4 inhibitors.
• 📉 The study found a very small absolute risk difference (about one additional PAD event per 10,000 patient-years) with SGLT2 inhibitors.
• ❓ A clear mechanism for a link between SGLT2 inhibitors and PAD events remains elusive, though hypotheses include diuretic or blood pressure effects.
• ✅ The findings suggest that while a real association may exist, it is likely rare, and the cardiovascular, heart failure, and kidney benefits of SGLT2 inhibitors likely outweigh this risk for most patients.

Transfusion Strategies in Acute MI

• 🎯 A meta-analysis of four trials, dominated by the MINT trial, compared restrictive versus liberal transfusion strategies in patients with acute MI and anemia.
• 📉 Liberal transfusion (hemoglobin < 10 g/dL) was not associated with improved survival or reduced MI at 30 days in unselected patients.
• ⏳ However, a survival advantage at 6 months was observed with liberal transfusion, driven by a reduction in cardiac death at day 30.
• 💡 The authors suggest that liberal transfusion may benefit a subset of patients, particularly those with ongoing ischemia or active bleeding, while less enthusiastic about transfusing stable patients with hemoglobin around 9 g/dL.